Objective: Correlate the necropsy diagnosis with the history, diagnostic findings, and clinical course of dyspneic cats with primary lung parenchymal disease. Design: Retrospective study. Setting: Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania. Animals: Client-owned cats over 6 months of age hospitalized in the Intensive Care Unit (ICU) with a primary problem of respiratory distress that had pulmonary parenchymal disease on thoracic radiographs, and a complete necropsy. Interventions: None. Measurements and main results: Cats included were assigned into 2 groups based on the pulmonary histopathology: inflammatory (n 5 8) and neoplastic (n 5 7) disease. No statistical difference was found between the groups with regard to age, body weight, clinical signs, duration of clinical signs, physical examination findings, thoracic radiography, duration of hospitalization, treatment, and outcome. Cats with neoplasia had a statistically higher mean total white blood cell count (26.60 k/mL AE 10.41) than those with inflammatory lung disease (11.59 k/mL AE 4.49; P 5 0.026). Cats with bacterial or viral pulmonary disease had a significantly shorter median duration of illness (5 days, range 1-7 days) than all other cats (30 days, range 7-365 days; P 5 0.0042). Ultrasound guided pulmonary fine-needle aspiration (FNA) provided an accurate diagnosis in 5/5 cases. Conclusions: Forty-seven percent of cats with pulmonary parenchymal disease had neoplasia. The clinical diagnosis was difficult to obtain ante-mortem; lung FNA appeared to be the most helpful diagnostic tool in these cases. (J Vet Emerg Crit Care 2005; 15(1): 38-47)
No abstract
Objectives: 1) Describe the clinical course and diagnostic findings of cats with histopathologic evidence of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). 2) Identify risk factors for ALI/ARDS in cats. Animals: Sixty‐five client‐owned cats with moderate to severe interstitial pneumonia, pneumonitis or alveolitis consistent with ALI/ARDS on post‐mortem examination and clinical evidence of respiratory compromise. Procedure: Retrospective evaluation of medical records, postmortem examination and radiographs. Results: Cats in this study tended to be middle aged (mean 6.5±4.9 years). They had a short duration of illness (median 4 days; range 0–120 days) and of dyspnea (median 1 day; range 1–7 days). On presentation, the cats were tachypneic (mean respiratory rate 53±23 bpm) and relatively bradycardic (mean heart rate 166±43 bpm). The majority of cats were dyspneic (n=39) at presentation; all others developed respiratory difficulties during hospitalization. The mean white blood cell count was within normal limits (14.6±14.0 k/μL); 8 cats had a leukocytosis and 7 were leucopenic. Clinical findings consistent with SIRS (n=39) and sepsis (n=10) were common. Thoracic radiographs were reviewed in 31 cats and alveolar disease was the most frequent pattern (105 lung lobes) followed by interstitial disease (86 lung lobes). No cat had normal thoracic radiographs throughout hospitalization. Underlying disease was not identified on post‐mortem examination in 15 cats (23%), but in the remaining cats underlying diseases included infectious systemic disease (n=11), neoplasia (n=8), respiratory (n=8) and urinary (n=7) system disorders, acute pancreatitis (n=7), hepatic diseases (n=5), major trauma (n=4), sepsis (n=3), CNS (n=2) and other systems (n=5). Nine cats had more then one underlying process. Conclusions: This study describes a naturally‐occurring syndrome of ALI/ARDS in cats analogous to that which occurs in dogs and humans. In cats, ALI/ARDS occurs as a sequela of a variety of underlying systemic diseases, but in approximately one‐quarter of patients an underlying cause is not identified at necropsy. It is important to consider ALI/ARDS in systemically ill cats who become dyspneic; in cats with pulmonary disease with acute worsening of respiratory status and in cats with pulmonary infiltrates for which no other cause can be identified.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.